NCT03430999View on ClinicalTrials.gov

SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 7, 2017

Primary Completion Date

December 18, 2017

Study Completion Date

December 18, 2017

Conditions
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions
DRUG

Calmangafodipir

Single ascending doses of 2 μmol/kg, 5 μmol/kg, and 10 μmol/kg

DRUG

Placebo

Placebo

Trial Locations (1)

90630

WCCT Global, Cypress

Sponsors
All Listed Sponsors
lead

Egetis Therapeutics

INDUSTRY

NCT03430999 - SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects | Biotech Hunter | Biotech Hunter